A carregar...
Slowly Signaling G Protein–Biased CB(2) Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence
The CB(2) cannabinoid agonist LY2828360 lacked both toxicity and efficacy in a clinical trial for osteoarthritis. Whether LY2828360 suppresses neuropathic pain has not been reported, and its signaling profile is unknown. In vitro, LY2828360 was a slowly acting but efficacious G protein–biased CB(2)...
Na minha lista:
| Publicado no: | Mol Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5749492/ https://ncbi.nlm.nih.gov/pubmed/29192123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.117.109355 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|